Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002319874 | SCV002608865 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-11-13 | criteria provided, single submitter | clinical testing | The c.307T>A (p.S103T) alteration is located in exon 5 (coding exon 2) of the FLCN gene. This alteration results from a T to A substitution at nucleotide position 307, causing the serine (S) at amino acid position 103 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003099176 | SCV003028428 | uncertain significance | Birt-Hogg-Dube syndrome | 2021-08-28 | criteria provided, single submitter | clinical testing | This sequence change replaces serine with threonine at codon 103 of the FLCN protein (p.Ser103Thr). The serine residue is moderately conserved and there is a small physicochemical difference between serine and threonine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with FLCN-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |